<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440956</url>
  </required_header>
  <id_info>
    <org_study_id>CL01</org_study_id>
    <nct_id>NCT04440956</nct_id>
  </id_info>
  <brief_title>An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours</brief_title>
  <official_title>Positron Emission Tomography (PET) Imaging of Patients With Low &amp; Intermediate Grade Neuroendocrine Tumors Using 64Cu-SARTATE: A Single Centre, Open-Label, Non-Randomized, Phase-0 Microdosing Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarity Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarity Pharmaceuticals Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to examine the safety and potential effectiveness of a
      drug molecule called 64Cu-SARTATE as a potential new way to detect neuroendocrine cancers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Actual">February 25, 2016</completion_date>
  <primary_completion_date type="Actual">February 25, 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events related to 64Cu-SARTATE</measure>
    <time_frame>1 week post administration</time_frame>
    <description>Occurrence of adverse clinical, biochemical or haematological events assessed for up to 1 week post administration of 64Cu-SARTATE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of injected 64Cu-SARTATE dose found in organs of interest</measure>
    <time_frame>At 30 minutes following administration</time_frame>
    <description>Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of injected 64Cu-SARTATE dose found in organs of interest</measure>
    <time_frame>At 1 hour following administration</time_frame>
    <description>Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of injected 64Cu-SARTATE dose found in organs of interest</measure>
    <time_frame>At 4 hours following administration</time_frame>
    <description>Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of injected 64Cu-SARTATE dose found in organs of interest</measure>
    <time_frame>At 24 hours following administration</time_frame>
    <description>Percentage of injected 64Cu-SARTATE dose found in organs of interest via whole body PET scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorbed organ dose</measure>
    <time_frame>At 30 minutes following administration</time_frame>
    <description>Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorbed organ dose</measure>
    <time_frame>At 1 hour following administration</time_frame>
    <description>Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorbed organ dose</measure>
    <time_frame>At 4 hours following administration</time_frame>
    <description>Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorbed organ dose</measure>
    <time_frame>At 24 hours following administration</time_frame>
    <description>Absorbed organ doses expressed as micro Sv/MBq of administered 64Cu-SARTATE, and whole body dose expressed as milliSv/200MBq of administered dose as assessed using whole body PET scan (composite outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstration of known malignancy</measure>
    <time_frame>30 minutes, 1 hour, 4 hours and 24 hours following administration</time_frame>
    <description>Whether 64Cu-SARTATE PET/CT scans demonstrate known sites of 68Ga-DOTATATE avid malignancy with equivalent or greater tumor to background ratios, where background uptake is that found in a non-tumor containing area of interest as decided upon by the nuclear medicine physician at the time of scan assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake in non-physiological, non-tumor containing tissues</measure>
    <time_frame>30 minutes, 1 hour, 4 hours and 24 hours following administration</time_frame>
    <description>Whether 64Cu-SARTATE PET/CT scans demonstrate any non-physiological, non-tumor containing tissues with uptake greater than 1.5 x that of the background, where background uptake is defined as in secondary endpoint.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200MBq of 64Cu-MeCOSar-Octreotate (&quot;64Cu-SARTATE&quot;) given as a single bolus intravenous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-SARTATE</intervention_name>
    <description>200MBq of 64Cu-MeCOSar-Octreotate (&quot;64Cu-SARTATE&quot;) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>64Cu-MeCOSar-Octreotate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Age greater than or equal to 18 years

          3. Life expectancy greater than or equal to 8 weeks

          4. Low and Intermediate Grade (Ki-67 index &lt;20%) neuroendocrine tumors (NET)

          5. At least one site of active somatostatin receptor positive malignancy, as demonstrated
             on the pre-study 68Ga-DOTATATE PET/CT scan performed as part of routine clinical care

          6. Subjects with an estimated glomerular filtration rate (eGFR) greater than 60ml/min as
             measured using the MDRD formula (Modification of Diet in Renal Disease).

          7. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2

        Exclusion Criteria:

          1. Pregnant or breastfeeding females

          2. Known sensitivity or allergy to somatostatin analogues

          3. Subjects who have received interventional treatment for their NET in the interval
             between 68Ga-DOTATATE PET/CT &amp; 64Cu-SARTATE PET/CT scan

          4. Treatment with long acting somatostatin analogues within 28 days prior to the
             administration of Investigational Product

          5. Treatment with short acting somatostatin analogues within 24hrs prior to the
             administration of Investigational Product

          6. QTc interval greater than 0.44seconds as measured by screening ECG

          7. Any serious medical condition which the investigator feels may interfere with the
             procedures or evaluations of the study

          8. Patients unwilling or unable to comply with protocol or with a history of
             non-compliance or inability to grant informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

